About Acadia
Acadia is a company based in San Diego (United States). It operates as a Direct-to-Consumer (D2C). Acadia has completed 1 acquisition, including ​​Cersci Therapeutics. Acadia offers products and services including NUPLAZID® and DAYBUE®.
- Headquarter San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website acadia.com
- Social LinkedIn
- Investments & Acquisitions
Products & Services of Acadia
Acadia offers a comprehensive portfolio of products and services, including NUPLAZID® and DAYBUE®.
Treatment for Parkinson’s Disease Psychosis is provided by NUPLAZID®.
Treatment for Rett Syndrome is offered through DAYBUE® product.
People of Acadia
248 people are tracked at Acadia (114 in leadership, 8 in board & advisors, 126 in team).
| Name | Role | Group |
|---|---|---|
Stephen R. Davis | President & CEO | Leadership |
Mathias Becquart | Head Of Commercial, Strategy And Ops | Leadership |
Lynne Rueter | Executive Director | Leadership |
Christine Hendrick | Director Commercial Operations | Leadership |
Caryn Coin Westenberger | Director Talent Acquisition | Leadership |
Suresh Kandula | Director, Systems And Operations | Leadership |
Kena Colon | Vice President | Leadership |
Jay C. | Associate Director, Commercial Effectiveness And Training | Leadership |
Anagha Gupte Chokshi | Associate Director, IT Business Partner | Leadership |
Francois Laurent - Finance | Senior Director Fp&a | Leadership |
Nancy Andrews | Director - People Business Partner | Leadership |
Kristen Hoskins | Executive Director, Talent & Strategic Execution | Leadership |
Prasoon Pancholi | Vp, Head Of Commercial Insights, Analytics And Operations | Leadership |
Kathie M. Bishop | SVP, Head of Rare Disease and External Innovation | Leadership |
Mark Schneyer | SVP, Business Development and Chief Business Officer | Leadership |
Lambros Chrones | Senior Medical Director, Medical Affairs | Leadership |
Holly Valdiviez | Senior Vice President & Head of Sales | Leadership |
Konstantina Katcheves | Chief Business And Strategy Officer | Leadership |
Mike Kaull | Vice President, IT | Leadership |
Rob Ackles | SVP & Chief People Officer | Leadership |
228 more people are available in the full profile.
Complete people profiles for Acadia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acadia
Acadia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ​​Cersci Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Non-opioid therapeutics for acute and chronic pain treatment are developed. | cersci.com | Dallas, United States | 2015 | Aug 2020 | $52.5M |
Complete acquisition details for Acadia
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Acadia
Websites that share an audience with Acadia (acadia-pharm.com).
Websites whose visitors overlap most with Acadia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acorda.com | 100% | – | #13,560,187 | View details | |
| arenapharm.com | 97% | – | – | View details | |
| pacira.com | 74% | 39.1K | #1,306,031 | View details |
Similar companies to Acadia
10 companies that operate in the same segment as Acadia (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acadia
Acadia is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Acadia Pharmaceuticals is dedicated to advancing therapies for neurological disorders and rare diseases where limited treatment options exist. The companys efforts are centered on conditions such as Parkinsons Disease Psychosis and Rett Syndrome, with FDA-approved treatments like NUPLAZID and DAYBUE already in their portfolio. Additionally, a robust pipeline is maintained, targeting Alzheimers Disease Psychosis and other unmet needs through mid- to late-stage and early-stage programs. Operations span across multiple therapeutic areas, ensuring that innovative solutions are brought to underserved communities globally. Support for patients and families is also provided through resources and tools aimed at improving daily life.
Acadia offers NUPLAZID® and DAYBUE®.
Acadia has made 1 acquisition, including ​​Cersci Therapeutics.